• Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
Search
Arvinas Logo
Arvinas logo
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
Search
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
  • Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
11DecDecember 11, 2024

SABCS 2024

10DecDecember 10, 2024

Evaluation of the Combination of Vepdegestrant, a PROTAC Estrogen Receptor Degrader, Plus Palbociclib in CDK4/6 Inhibitor–Resistant Wild-Type and Estrogen Receptor Y537S–Mutant Patient-Derived Xenograft Models

18JunJune 18, 2024

Biennial International LRRK2 Meeting 2024

18JunJune 18, 2024

Development of Potent, Orally Bioavailable PROTAC® LRRK2 Degrader Molecules as Potential Disease Modifying Therapeutics for Neurodegeneration

13JunJune 13, 2024

EHA 2024

13JunJune 13, 2024

Oral ARV-393 is a BCL6 Degrading PROTAC® Efficacious as a Monotherapy in B-Cell Lymphoma Preclinical CDX and PDX Models

10AprApril 10, 2024

AACR 2024

05AprApril 5, 2024

The Discovery of ARV-393, a Potent, Orally Bioavailable BCL6-Targeting PROTAC® for the Treatment of NHL

09DecDecember 9, 2023

SABCS 2023

05DecDecember 5, 2023

Leveraging a Pharmacokinetic /Pharmacodynamic (PK/PD) Model to Guide Dose Optimization of Palbociclib in Combination With Vepdegestrant

  Prev1…3456Next  
Arvinas logo
  • Careers
  • Privacy Policy
  • Terms of Use
LinkedIn
X

Accessibility Statement

© 2026 Arvinas. All rights reserved.

Arvinas

You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

GO BACK
CONTINUE